Core Viewpoint - The company, 百奥赛图-B (02315), has seen a significant stock price increase of over 12% in a single day and approximately 30% over the past three days, indicating strong market interest and confidence in its recent developments [1] Group 1: AI-Driven Antibody Drug Development - The company has completed the localization deployment of its AI-driven antibody drug development platform, which is expected to enhance collaboration with its core 千鼠万抗 plan [1] - The integration of AI systems with the 千鼠万抗 plan aims to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library, thereby improving the efficiency of preclinical PCC molecule development [1] - This advancement is anticipated to propel the antibody discovery business into a new phase of development [1] Group 2: Collaboration with育世博 - The company has entered into an option and licensing agreement with 育世博 to systematically evaluate the BsADC project through a structured assessment mechanism [1] - This collaboration aims to accelerate the development process of the BsAD2C, a dual-target antibody drug conjugate [1]

Core Viewpoint - The company has initiated the "Thousand Mice, Ten Thousand Antibodies" program to develop antibodies targeting over 1,000 potential drug targets, leveraging AI technology to enhance its research and development capabilities [1] Group 1: Company Initiatives - The "Thousand Mice, Ten Thousand Antibodies" program was launched in 2020, focusing on developing antibodies using platforms like RenMab, RenLite, and RenNano [1] - By the end of 2024, the company aims to have obtained approximately 1,000,000 fully human antibody sequences, covering various forms such as monoclonal, bispecific, and nanobodies [1] - The company plans to expand its fully human antibody library to tens of millions in the future [1] Group 2: AI Integration - The company has completed the localized deployment of an AI-driven antibody drug development platform, which is fully integrated with the "Thousand Mice, Ten Thousand Antibodies" program [1] - An "antibody evolution tree" has been established, encompassing over 1,000 targets and 1,000,000 fully human antibody molecules, utilizing bioinformatics [1] - The ongoing integration of the "Thousand Mice, Ten Thousand Antibodies" program with the AI system is expected to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library [1]

Core Viewpoint - The company has initiated the "Thousand Mice, Ten Thousand Antibodies" program to develop antibodies targeting over 1,000 potential drug targets, leveraging its proprietary platforms for antibody development [1] Group 1: Antibody Development Program - The program aims to develop antibodies using the RenMab, RenLite, and RenNano platforms, with a goal of obtaining approximately 1,000,000 fully human antibody sequences by the end of 2024 [1] - The antibody library will include various forms such as monoclonal antibodies, bispecific antibodies, and nanobodies, characterized by high affinity, low immunogenicity, and favorable drug-like properties [1] - The company plans to expand its fully human antibody library to tens of millions in the future [1] Group 2: AI Integration - The company has completed the localization of its AI-driven antibody drug development platform, which is fully integrated with the "Thousand Mice, Ten Thousand Antibodies" program [1] - An "antibody evolution tree" has been established, covering over 1,000 targets and including 1,000,000 fully human antibody sequences, utilizing bioinformatics [1] - The ongoing integration of the AI system with the antibody development program aims to provide global pharmaceutical companies with more efficient research tools and a richer antibody library, enhancing the efficiency of preclinical PCC molecule development [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has entered into an option and licensing agreement with Yushibo to systematically evaluate the bispecific antibody-drug conjugate (BsADC) projects, aiming to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) [1] Group 1 - The agreement grants Yushibo an option to obtain global exclusive rights to two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1] - Specific financial terms of the agreement have not been disclosed [1]

Group 1 - The core viewpoint of the article highlights that 百奥赛图-B (02315.HK) experienced a significant intraday increase of over 11%, reaching a historical high of 44 HKD [2] - As of the time of reporting, 百奥赛图-B's stock price rose by 7.29%, trading at 42.38 HKD, with a transaction volume of 81.9068 million HKD [2]

Core Viewpoint - The stock of Baiaosaitu-B (02315) has seen a significant increase, reaching a new historical high of 44 HKD, with a current price of 42.50 HKD, reflecting a rise of 7.59% and a trading volume of 85.6693 million HKD [1][6]. Group 1 - On January 9, Baiaosaitu announced a licensing agreement with Yushibo to systematically evaluate the bispecific antibody-drug conjugate (BsADC) projects, aiming to accelerate the development of bispecific antibody dual-drug conjugates (BsAD2C) [1][6]. - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu [1][6]. - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1][6].

Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 11% during trading, reaching a historical high of 44 HKD, and is currently up 7.29% at 42.38 HKD with a trading volume of 81.9068 million HKD [1] Group 1: Agreement Details - On January 9, Baiaosaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC projects through a structured assessment mechanism [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1]

Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 11% during trading, reaching a new historical high of 44 HKD, and is currently up 7.29% at 42.38 HKD with a trading volume of 81.9068 million HKD [1] Group 1: Agreement Details - On January 9, Baiaosaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC projects through a structured assessment mechanism [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will receive additional payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1]

1月12日，百奥赛图涨14.87%，成交额4.25亿元。两融数据显示，当日百奥赛图获融资买入额2733.31万 元，融资偿还2783.88万元，融资净买入-50.57万元。截至1月12日，百奥赛图融资融券余额合计5579.88 万元。 资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分部识别有潜力成为候选药物的抗体，并就潜在治疗 性抗体分子对外授权或与合作伙伴合作。创新药开发分部研发创新药，专注肿瘤学和自身免疫性疾病治 疗。 责任编辑：小浪快报 融资方面，百奥赛图当日融资买入2733.31万元。当前融资余额5579.88万元，占流通市值的2. ...

Core Viewpoint - The announcement highlights a strategic collaboration between Baiaosaitu-B (02315) and Yushibo Co., Ltd. to accelerate the development of bispecific antibody-drug conjugates (BsAD2C) through a structured evaluation mechanism [1][2] Group 1: Agreement Details - The agreement grants Yushibo a right to obtain global exclusive licenses for two BsADC projects from Baiaosaitu [1] - Baiaosaitu will receive an upfront payment for the option, and subsequent payments will include option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and future product sales revenue sharing [1] Group 2: Collaboration Background - This agreement deepens the collaboration initiated earlier in the year, which focused on evaluating and screening bispecific antibodies and dual-load antibody-drug conjugate (ADC) candidates with therapeutic potential [1] - The combination of Baiaosaitu's RenLite fully human light chain antibody development platform and Yushibo's antibody-drug conjugate (AD2C) technology is seen as a promising technical pathway for the development of a new generation of BsAD2C [1] Group 3: Project Advancement - The collaboration aims to leverage the complementary strengths of both platforms to advance the design of next-generation ADC molecules, addressing limitations observed in traditional ADC projects [2] - The project team is steadily progressing through key evaluation milestones, with decisions based on ongoing research data and Yushibo's internal processes and option exercise criteria [2]